Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Zevra Therapeutics (ZVRA) Gains from Investment Securities: 2014-2025

Historic Gains from Investment Securities for Zevra Therapeutics (ZVRA) over the last 10 years, with Sep 2025 value amounting to $65.1 million.

  • Zevra Therapeutics' Gains from Investment Securities rose 57.43% to $65.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $222.5 million, marking a year-over-year increase of 277.07%. This contributed to the annual value of $6.0 million for FY2024, which is 25.82% down from last year.
  • According to the latest figures from Q3 2025, Zevra Therapeutics' Gains from Investment Securities is $65.1 million, which was down 56.69% from $150.4 million recorded in Q2 2025.
  • Zevra Therapeutics' 5-year Gains from Investment Securities high stood at $150.4 million for Q2 2025, and its period low was -$10.5 million during Q1 2022.
  • In the last 3 years, Zevra Therapeutics' Gains from Investment Securities had a median value of $12.4 million in 2023 and averaged $35.2 million.
  • Per our database at Business Quant, Zevra Therapeutics' Gains from Investment Securities plummeted by 17,290.16% in 2022 and then surged by 116,452.71% in 2025.
  • Quarterly analysis of 5 years shows Zevra Therapeutics' Gains from Investment Securities stood at $17,000 in 2021, then plummeted by 2,447.06% to -$399,000 in 2022, then surged by 98.25% to -$7,000 in 2023, then tumbled by 4,571.43% to -$327,000 in 2024, then soared by 57.43% to $65.1 million in 2025.
  • Its Gains from Investment Securities stands at $65.1 million for Q3 2025, versus $150.4 million for Q2 2025 and $7.4 million for Q1 2025.